Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Filament Health Corp
(OP:
FLHLF
)
0.0394
UNCHANGED
Streaming Delayed Price
Updated: 1:33 PM EST, Nov 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Filament Health Corp
< Previous
1
2
3
Next >
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
March 15, 2023
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.
Via
Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
February 27, 2023
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...
Via
Benzinga
[Video] Revolutionizing Mental Health: Filament Health CEO Discusses The Future Of Psychedelic Medicine
February 21, 2023
Cannabis enthusiasts and industry insiders alike will find the latest episode of Benzinga's Cannabis Insider show both informative and engaging.
Via
Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...
Via
Benzinga
Supply Partnerships: Filament's Psilocybin Trial In Canada, PharmAla's MDMA Program In Australia
February 14, 2023
Filament’s Psilocybin, Tested On Mild Cognitive Impairment By CAMH
Via
Benzinga
EXCLUSIVE: Defining 'Natural' Psychedelics, State Regulations & Ayahuasca's Benefits
January 26, 2023
(Part three of a three-part series) See previous stories: EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Via
Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
January 25, 2023
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?
Via
Benzinga
Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
January 23, 2023
Via
ACCESSWIRE
Psychiatry And Business Collaborate: European Psychedelics Trial Tackles Alcohol Addiction
January 20, 2023
Clinical-stage natural psychedelics developer Filament Health (OTCQB: FLHLF) and the Psychiatric Center Copenhagen’s collaborative clinical trial has been approved by the Danish Medicines Agency and is...
Via
Benzinga
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
January 10, 2023
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space.
Via
Benzinga
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
January 10, 2023
Via
ACCESSWIRE
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
EXCLUSIVE: The Psychedelics Debate Is 'Raging' As Filament Debuts Ayahuasca Pill
December 16, 2022
Part two of a three-part series. Previous story: Standardized Ayahuasca Pill Is Officially Here, Feast Yourself With The Exclusive Details & Insights
Via
Benzinga
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU
December 15, 2022
Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal.
Via
Benzinga
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
December 15, 2022
Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
December 13, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Filament Health to Present Live at VirtualInvestorConferences.com December 15th
December 13, 2022
Filament invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) Featured in Virtual Coverage of the KCSA Mental Health Investor Conference
December 13, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
December 06, 2022
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and...
Via
Benzinga
Natural Psychedelics Extraction & Standardization Obtains Two New US Patents
December 01, 2022
Clinical-stage psychedelics drug development company Filament Health Corp.
Via
Benzinga
Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup
November 15, 2022
Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics
Via
Benzinga
Filament Health Shares Q3 2022 Results, On Road To Becoming Industry's Natural Psilocybin Supplier
November 11, 2022
Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September...
Via
Benzinga
Psyched: Brock Pierce Joins Psychedelic VC, Colorado's Psychedelics Legalization, Zappy Zapolin's Open Letter & More
November 07, 2022
Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable'
Via
Benzinga
EXCLUSIVE: Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable'
November 04, 2022
Brock Pierce, the crypto billionaire, economist and philanthropist serving as chairman of the Bitcoin Foundation, has joined Jeremy Gardner’s psychedelics-focused venture fund Mystic Ventures as a...
Via
Benzinga
Filament Begins First Ever FDA-Approved Clinical Trial On Naturally-Derived Psychedelic Drugs
July 08, 2022
Clinical-stage natural psychedelics company Filament Health Corp.
Via
Benzinga
Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial
July 07, 2022
From
Filament Health Corp.
Via
Business Wire
Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
June 16, 2022
For those unaware, Canada provides a legal way for patients presenting unresolved mental health issues to receive psychedelic-assisted treatment.
Via
Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
June 15, 2022
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.
Via
Benzinga
Two Psychedelics Drug Development Companies Work To Produce Novel Plant-Based Compounds For Mental Health Disorders
June 09, 2022
Filament Health Corp. (OTCQB: FLHLF) and Jaguar Health, Inc. (NASDAQ: JAGX) have signed a letter of intent for a collaboration agreement.
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.